Postdoctoral Research Associate in Nanomedicine, Northeastern University, USA
Visiting Scientist, Dept of Radiation Oncology, Dana Farber Cancer Institute, USA
Received Date: September 26, 2014; Accepted Date: September 29, 2014; Published Date: October 02, 2014
Citation: Tangutoori S. (2014) The Cytoskeleton as Biomarker: Angiosarcoma- Cytoskeleton. J Mol Biomark Diagn 5:i101. doi:10.4172/2155-9929.1000I101
Copyright: © 2014 Tangutoori S. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use,distribution, and reproduction in any medium, provided the original author and source are credited
Visit for more related articles at Journal of Molecular Biomarkers & Diagnosis
The cytoskeleton as biomarker: The cytoskeleton often serves as a reliable biomarker of stress and antimitotic effects induced by various classes of anticancer drugs on tumor cells. The organization of cellular cytoskeleton of an angiosarcoma cell, MS1-VEGF, is depicted using FITC-β-tubulin antibody as the immunofluorescence indicator. The cytoskeletal changes can be probed before and after cancer therapy to detect the extent of vascular disruption and vascular shutdown. Green represents the cytoskeleton, blue represent the nucleus of the angiosarcoma cell.
Image acquired in Bouve College of health Sciences, Department of Pharmaceutical Sciences, Campbell Lab (31 MU); Northeastern University, Boston-MA.